Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Study Overview
=================
Brief Summary
-----------------
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Detailed Description
-----------------
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. Registration after informed consent. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood Regular monitoring disease status and update of survival status Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Official Title
-----------------
A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center

Conditions
-----------------
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin

Intervention / Treatment
-----------------
* Drug: Chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 20 years Patients requiring systemic chemotherapy with curative intent Written informed consent Exclusion Criteria: Myeloid malignancy Multiple myeloma Patients do not require systemic chemotherapy with curative intent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lymphoma<br>Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled. | Drug: Chemotherapy<br>* Systemic chemotherapy with curative intent<br>* Other names: Treatment;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate | response to chemotherapy | 3 months after chemotherapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Time to relapse/progression or any kinds of death | 3 year | 
| Overall survival | Time to any kinds of death | 3 year | 
| Biomarker | Development of biomarker predicting response and survival outcome | 3 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lymphoma, cohort, serum, cell-free DNA